A phase II study evaluating the efficacy and the safety of first-line chemotherapy combined with TG4010 and nivolumab in patients with advanced non-squamous Non-Small-Cell Lung Cancer (NSCLC)

×

Error message

  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (line 53 of /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (line 95 of /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
A phase II study evaluating the efficacy and the safety of first-line chemotherapy combined with TG4010 and nivolumab in patients with advanced non-squamous Non-Small-Cell Lung Cancer (NSCLC)
EU record number: 
B/BE/17/BVW1
EudraCT number: 
2016-005115-41
Company / Sponsor: 
Transgene
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
Use as a chemotherapy in combination with the monoclonal antibody Nivolumab in patients with advanced non-squamous Non-Small-Cell Lung Cancer (NSCLC)
Genetic modification: 
Sequences coding for human mucine 1 (MUC1) antigen and interleukin-2 (IL2)
Method of transfer of nucleic acid of interest: 
Attenuated Vaccinia Virus (Ankara Strain)
Route of administration: 
Subcutaneous
Locations in Belgium: 
Centre Hospitalier de l’Ardenne, Libramont
Nr of subjects: 
5 patients foreseen in Belgium
Foreseen duration: 
2 years
Type of procedure: 
Contained use and Deliberate release

Information for the public

Information related to the decision procedure